ENDV (Endonovo Therapeutics) Moat Score: 2/10 (As of Jun. 26, 2026)


What is Endonovo Therapeutics Moat Score?

Endonovo Therapeutics ENDV -99.00% Moat Score is 2 as of Jun. 26, 2026. The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, Endonovo Therapeutics ranks better than 58.12% on this metric.

Endonovo Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Endonovo Therapeutics has No Moat: Endonovo Therapeutics Inc has limited market presence and lacks significant competitive advantages such as economies of scale, intellectual property, or regulatory barriers, leading to a transient competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Endonovo Therapeutics might have No Moat - Very weak/transient advantages.

Endonovo Therapeutics  (OTCPK:ENDV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Endonovo Therapeutics Moat Score Related Terms

ENDV vs RGBP, IOBTQ, CNBX: Moat Score Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Endonovo Therapeutics (ENDV) has a Moat Score of 2 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Endonovo Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Endonovo Therapeutics' Moat Score too high?
Endonovo Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Endonovo Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Endonovo Therapeutics ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint.
How does Endonovo Therapeutics' Moat Score compare to RGBP and IOBTQ?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #588 out of 1404 companies for Moat Score. This puts Endonovo Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Endonovo Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Endonovo Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Moat Score is 2 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.